Ivermectin sales in Valle del Cauca, Colombia, patterns of AEs, and other background re López-Medina et al. 2021
Scheim et al., OSF Preprints (Preprint) (meta analysis)
Scheim et al., Ivermectin sales in Valle del Cauca, Colombia, patterns of AEs, and other background re López-Medina et al..., OSF Preprints (Preprint) (meta analysis)
Analysis of several issues with López-Medina et al. including the atypical adverse effects in the control arm and population use of ivermectin.
Currently there are 95 ivermectin studies
and meta analysis shows:
Scheim et al., 11 Mar 2021, preprint, 1 author.
Abstract: Supplementary data re López-Medina et al. 2021
David E Scheim a
Table S1. Sales of Ivermectin in liquid and capsule form in the Colombian state of Valle del Cauca, encompassing
the study region, from January 2019 through November 2020.1 Units of liquid IVM were bottles each containing 5
ml of 0.6% IVM, and units of capsules were blister packs of 7 pills, 3 mg each. On July 9, 2020, a week before the LopezMedina et al. study began recruiting patients in Cali, its mayor, Jorge Iván Ospina, announced that his city would begin
distributing 10,000 doses of IVM to COVID-19 patients the following day. With IVM available over the counter (OTC)
in Colombia without prescription, sales of IVM quintupled in Valle del Cauca from June to July 2020. Sales of IVM
during the study period of July through November 2020 totaled 154,919 units (each unit about one dose), 1.6 times the
number of COVID-19 cases (95,387, see Table S2) during that period.
Table S2. COVID-19 cases in the Colombian state of Valle del Cauca, encompassing the study region, from June
through December 2020, by month.2
Number of cases
Table S3. Summary of adverse effects associated with IVM as reported in eTable 7 of López-Medina et al.
Dizziness (number, %)
Diarrhea (#, %)
Nausea #, %)
Disturbances of vision, any (#, %) 44 (16.0%)
Photophobia (#, %)
Blurry vision (#, %)
David E. Scheim, PhD (email: email@example.com) is a commissioned officer in the US Public Health Service,
Page 1 of 4
Figure S1. Google trends for ivermectina v. vacuna covid in the Colombian state of Valle del Cauca, encompassing
the study region, during and prior to the Lopez-Medina study enrollment period of July 15 through November 30,
2020. The number of Google searches for ivermectina (Spanish for ivermectin) spiked from 2 times to 33 times that for
COVID vaccine (vacuna covid) from the last week in June to the first week of July 2020. The total number of searches
for ivermectina in the weeks beginning July through November 2020 was 2.7 times greater than that number for vacuna
Table S3. Timeline of breaches of boundaries between treatment and placebo groups in Lopez-Medina et al.
Oct. 20, 2020
“On October 20, 2020, the lead pharmacist observed that a labeling error had
occurred between September 29 and October 15, 2020, resulting in all patients
receiving ivermectin and none receiving placebo during this time frame.” This
affected 75 patients, 38 of which were randomized to receive placebo. These 75
patients were excluded in the analysis for the primary endpoint but included in
several other tables presented in supplement 2.
paper, p. 3; study
protocol, p. 43
Aug 26, 2020
This is the date through which “the placebo was a mixture of 5% dextrose in
saline and 5% dextrose in distilled water.” This placebo solution was used for
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.